Engineered antibodies

@article{Hudson2003EngineeredA,
  title={Engineered antibodies},
  author={P. Hudson and C. Souriau},
  journal={Nature Medicine},
  year={2003},
  volume={9},
  pages={129-134}
}
Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as highlighted by recent approvals from the US Food and Drug Administration. Recombinant antibodies have been reduced in size, rebuilt into multivalent molecules and fused with, for example radionuclides, toxins, enzymes, liposomes and viruses. The emergence of recombinant technologies has revolutionized the selection, humanization and production of antibodies, superseding hybridoma technology and allowing… Expand
Engineered antibody fragments and the rise of single domains
TLDR
There is tremendous potential for all antibody fragments either as robust diagnostic reagents, or as nonimmunogenic in vivo biopharmaceuticals with superior biodistribution and blood clearance properties. Expand
Antibody engineering: facing new challenges in cancer therapy
TLDR
This review considers the structure of different types of recombinant antibodies, their mechanism of action and how their efficacy has been increased using a broad array of approaches, and focuses on the additional benefits offered by the use of gene therapy methods for the in vivo production of therapeutic antibodies. Expand
Recombinant Antibodies as Therapeutic Agents
TLDR
The present review focuses on the structural and functional characteristics of mAbs and their fragments, and also provides a walk through the most important methods used in antibody selection. Expand
Molecular engineering of antibodies for therapeutic and diagnostic purposes
TLDR
Efforts are regularly made by researchers to improve or modulate antibody recognition properties, to adapt their pharmacokinetics, engineer their stability, and control their immunogenicity. Expand
Engineering Antibodies for Clinical Applications in Cancer
TLDR
The mechanistic approach to making new molecules for antibody imaging and therapy of cancer is illustrated by examples of radioimmunotherapy and antibody-directed enzyme prodrug therapy developed by the authors. Expand
Antibody Engineering for Pursuing a Healthier Future
TLDR
Recent advances in antibody engineering techniques together with antibody fragments, display technologies, immunomodulation, and broad applications of antibodies are discussed to enhance innovative antibody production in pursuit of a healthier future for humans. Expand
Metrics for antibody therapeutics development
TLDR
The expansion of therapeutic antibody use through supplemental marketing approvals and the increase in the study of therapeutics derived from alternative antibody formats are discussed, providing an overview of the field and context for the evaluation of on-going and prospective mAb development programs. Expand
Multivalent antibodies: when design surpasses evolution.
TLDR
Novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity and further discuss their promise as agents for in vivo diagnostics and therapy. Expand
Recombinant antibodies for cancer diagnosis and therapy
TLDR
Developments in the design, production and clinical use of recombinant antibodies for cancer diagnosis and therapy are described and innovative affinity maturation methods have been developed which enable rapid selection of extremely high-affinity reagents. Expand
The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications
TLDR
The potential of sdAbs selected using in vitro display systems and their use in multiple applications are described, including small size, high thermostability, stable folding in the nucleus and cytosol and long CDR3 regions which have access to cavities or clefts on the surface of proteins. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 80 REFERENCES
Recombinant antibodies for cancer diagnosis and therapy.
TLDR
Developments in the design, production and clinical use of recombinant antibodies for cancer diagnosis and therapy are described and innovative affinity maturation methods have been developed which enable rapid selection of extremely high-affinity reagents. Expand
Bispecific human IgG by design.
  • P. Carter
  • Biology, Medicine
  • Journal of immunological methods
  • 2001
TLDR
A robust technology for the creation of bispecific IgG has recently been developed that virtually precludes IgG contaminants, as reviewed here, and this technology is anticipated to spur the clinical development of bisPespecific IgG and other bifunctional Fc-containing molecules such as antibody/immunoadhesin hybrids and bispespecific immunoadhesins. Expand
Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA
TLDR
This emerging approach centres on targeting CD22 on human B-cells with a monoclonal antibody (mAb) conjugated to a cytotoxic RNAse, which elicits potent and specific killing of the lymphoma cells in vitro and in human lymphoma models in severe combined immune deficiency mice. Expand
High-throughput generation and engineering of recombinant human antibodies.
TLDR
It is demonstrated that since HuCAL-scFv antibodies are expressed in high levels in Escherichia coli, automated panning and screening in miniaturised settings (96- and 384-well format) have now become feasible and HuCal is a very convenient source of human antibodies for various applications. Expand
Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
TLDR
It is demonstrated that it is possible to customize the pharmacokinetic properties of a Fab' while retaining its antigen binding activity and all PEGylated Fab' molecules were as efficacious in reducing oedema as the original monoclonal antibody. Expand
Natural and designer binding sites made by phage display technology.
TLDR
This application of phage display technology is reviewed, and the many other antibody-engineering avenues this technology offers are highlighted. Expand
Antibody‐guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells
TLDR
Progress is described in the development of a system based on a β‐glucosidase enzyme in combination with a naturally occurring “prodrug,” the sugar linamarin, which releases the cytotoxin cyanide, which generates cyanide. Expand
Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein.
TLDR
Sequence analysis of the intracellular antibody scFv panels revealed a sequence conservation indicating an intrACEllular antibody consensus for both VH and VL, which could form the basis for the de novo synthesis of intracesllular antibody libraries to be used with intrace cellular antibody-capture technology. Expand
Toxin-labeled monoclonal antibodies.
  • R. Kreitman
  • Medicine
  • Current pharmaceutical biotechnology
  • 2001
TLDR
Two recombinant immunotoxins, LMB-2 and BL22 have exhibited clinical activity in patients with hematologic malignancies, with less vascular leak syndrome and probably less immunogenicity than the larger conventional immunotoxin conjugates. Expand
Clinical Applications of Phage-Derived sFvs and sFv Fusion Proteins
TLDR
Fusion proteins are developed which use MFE-23 to deliver a therapeutic moiety and MFE::TNFα aims to reduce sequestration and increase tumor concentrations of systemically administered TNFα. Expand
...
1
2
3
4
5
...